Program
TYK2 Inhibitor
Its studies are mostly in Psoriasis, led by Usynova Pharmaceuticals.
Furthest: no phase, since Nov 14, 20251 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Usynova Pharmaceuticals | 11 open or running | no phasesince Nov 14, 2025 | Nov 14, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2025First study: no phase study in Plaque PsoriasisFirst studyNCT07234591 · 140 planned · China
TargetBeta
TYK2 →read by rule
“Any agent that inhibits the non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2).”NCIt, by rule
Other programs on TYK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| deucravacitinibrule | Bristol-Myers Squibb | phase 4 | 60 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| D-2570rule | InventisBio | phase 3 | 13 |
| HS-10374 | Hansoh Pharmaceutical Group | phase 3 | 6 |
| TQH3906 | Sino Biopharmaceutical | phase 3 | 6 |
| FXS5626 | Fosun Pharma | phase 3 | 3 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07234591Plaque Psoriasis · China | – | Recruiting | Apr 30, 2026 | 140 |
How it is read
Names in the registry
- “Tyk2 inhibitor”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.